Citace podle APA

Tanaka, S., & Uchino, J. (2019). Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer. Transl Lung Cancer Res.

Styl Chicago

Tanaka, Satomi, a Junji Uchino. "Erlotinib As Standard Adjuvant Therapy for Resectable EGFR Mutation-positive Non-small Cell Lung Cancer." Transl Lung Cancer Res 2019.

Citace podle MLA

Tanaka, Satomi, a Junji Uchino. "Erlotinib As Standard Adjuvant Therapy for Resectable EGFR Mutation-positive Non-small Cell Lung Cancer." Transl Lung Cancer Res 2019.

Upozornění: Tyto citace jsou generovány automaticky. Nemusí být zcela správně podle citačních pravidel..